Dec 3, 1977

Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions

B SpeckJ J van Rood


29 patients with severe aplastic anaemia were treated with either antilymphocyte globulin (A.L.G.) alone (15 patients) or A.L.G. followed by infusion of allogeneic bone-marrow (14 patients). The overall response to both forms of treatment in terms of 1-year survival was 55%; 12 of the 29 patients showed a sustained haematological improvement, during a period of observation of up to 4 1/2 years. No potentially fatal complications were observed. None of the bone-marrow infusions led to a permanent "take" or graft-versus-host disease. How A.L.G. acts is unknown, but our findings accord with the hypothesis that, in a substantial proportion of cases of aplastic anaemia, unspecified autoimmune reactions block the development of residual stem cells A.L.G. seems to offer a good chance of survival, especially for those patients who do not have HLA-matched siblings. Its value should be further established.

  • References5
  • Citations66


Mentioned in this Paper

Aplastic Anemia
Graft-vs-Host Disease
Retrograde Degeneration
Antilymphocyte Globulin
Graft-Versus-Host Disease Pathway
Complete Blood Count
Hypoplastic Anemia
Antilymphocyte Serum
Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine)
Transplantation, Homologous

About this Paper

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.